董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yi Lu | 男 | Chairman of the Board and Chief Executive Officer | 59 | 未披露 | 670.80 | 2025-10-08 |
| Mingyue Cai | 男 | Independent Director | 47 | 未披露 | 未持股 | 2025-10-08 |
| Jing Zhang | 女 | Independent Director | 46 | 未披露 | 未持股 | 2025-10-08 |
| Steven I Fang Cheng | 男 | Chief Technology Officer and Director | 44 | 未披露 | 74.26 | 2025-10-08 |
| Cheang I Kei | 女 | Independent Director | 29 | 0.80万美元 | 未持股 | 2025-10-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yi Lu | 男 | Chairman of the Board and Chief Executive Officer | 59 | 未披露 | 670.80 | 2025-10-08 |
| Mingze Yin | 男 | Chief Financial Officer | 35 | 16.17万美元 | 未持股 | 2025-10-08 |
| Steven I Fang Cheng | 男 | Chief Technology Officer and Director | 44 | 未披露 | 74.26 | 2025-10-08 |
董事简历
中英对照 | 中文 | 英文- Yi Lu
-
Yi Lu，自2022年11月起担任Advanced Biomed Inc.首席科学官兼董事长。他自2014年6月起担任Advanced Biomed Taiwan的董事长兼首席科学官。从2020年1月到2022年10月，他担任HFC Semiconductor的董事长。Lu博士此前曾担任Nextchip Semiconductor Corporation（一家专门从事集成电路生产的半导体代工厂）的董事长（2016年2月至2019年12月）。他带领公司投资200亿元，建成安徽省首条12英寸集成电路生产线。从2004年1月到2007年12月，他是Cypress Semiconductor的高级执行官。从2001年5月到2004年1月，他是Cascade Semiconductor（被Cypress Semiconductor Corporation （Nasdaq： CY）收购）的创始人、董事长兼首席执行官。
Yi Lu has served as Chairman of the Board since November 2022 and as Chief Executive Officer since March 2024. He has been the Chairman and Chief Science Officer of Advanced Biomed Taiwan since June 2014. He was the Chairman of HFC Semiconductor from January 2020 to October 2022 and was responsible for the company's strategic development. Dr. Lu previoly served as Chairman of Nextchip Semiconductor Corporation, a semiconductor foundry specializing in integrated circuit production, from February 2016 to December 2019 and led the company to launch the first 12 inch integrated circuit production line in Anhui Province with an investment of RMB20 billion. From January 2004 to December 2007, he was the senior executive of Cypress Semiconductor, overseeing the company's biness operation. From May 2001 to January 2004, he was the founder, Chairman and CEO of Cascade Semiconductor, which was acquired by Cypress Semiconductor Corporation (Nasdaq: CY), and managed the overall operations of the company. Dr. Lu received a Doctor of Philosophy from the University of Florida in 1994. - Yi Lu，自2022年11月起担任Advanced Biomed Inc.首席科学官兼董事长。他自2014年6月起担任Advanced Biomed Taiwan的董事长兼首席科学官。从2020年1月到2022年10月，他担任HFC Semiconductor的董事长。Lu博士此前曾担任Nextchip Semiconductor Corporation（一家专门从事集成电路生产的半导体代工厂）的董事长（2016年2月至2019年12月）。他带领公司投资200亿元，建成安徽省首条12英寸集成电路生产线。从2004年1月到2007年12月，他是Cypress Semiconductor的高级执行官。从2001年5月到2004年1月，他是Cascade Semiconductor（被Cypress Semiconductor Corporation （Nasdaq： CY）收购）的创始人、董事长兼首席执行官。
- Yi Lu has served as Chairman of the Board since November 2022 and as Chief Executive Officer since March 2024. He has been the Chairman and Chief Science Officer of Advanced Biomed Taiwan since June 2014. He was the Chairman of HFC Semiconductor from January 2020 to October 2022 and was responsible for the company's strategic development. Dr. Lu previoly served as Chairman of Nextchip Semiconductor Corporation, a semiconductor foundry specializing in integrated circuit production, from February 2016 to December 2019 and led the company to launch the first 12 inch integrated circuit production line in Anhui Province with an investment of RMB20 billion. From January 2004 to December 2007, he was the senior executive of Cypress Semiconductor, overseeing the company's biness operation. From May 2001 to January 2004, he was the founder, Chairman and CEO of Cascade Semiconductor, which was acquired by Cypress Semiconductor Corporation (Nasdaq: CY), and managed the overall operations of the company. Dr. Lu received a Doctor of Philosophy from the University of Florida in 1994.
- Mingyue Cai
-
Mingyue Cai于2020年2月25日被任命为董事会董事。Cai先生曾任深圳市Yitu安全技术有限公司副总裁，该公司是一家从事人工智能开发和应用的中国公司。2009年11月至2017年8月，他在如皋港口集团有限公司（Rugao Port Group Co.，Ltd.）担任行政总监，该公司是一家专注于港口物流、工业园区建设和木材、煤炭和矿石贸易的中国公司。2004年6月至2009年10月，Cai先生在上海Rishan环保科技有限公司担任经理，该公司是一家经销和零售环保清洁产品的中国公司。Cai先生拥有行政管理学士学位。
Mingyue Cai has served as independent director and the Chair of the Nominating and Corporate Governance Committee since February 2025. Mr. Cai has been the Vice President at Yitu Safety Technology (Shenzhen) Co., Ltd., a PRC company engages in artificial intelligence development and application. From February 2020 to April 2024, Mr. Cai worked as an independent director and the chair of compensation committee of GD Culture Group Limited (NASDAQ: GDC). From November 2009 to Augt 2017, he was an administrative director at Rugao Port Group Co., Ltd., a PRC company that foces on port logistics, indtrial park construction and timber, coal and ore trade. From June 2004 to October 2009, Mr. Cai worked as a manager at Shanghai Rishan Environmental Protection Technology Co., Ltd., a PRC company that distribute and retail environmentally friendly cleaning products. Mr. Cai graduated from China Central Radio & TV University in 2015 with a major in administration. - Mingyue Cai于2020年2月25日被任命为董事会董事。Cai先生曾任深圳市Yitu安全技术有限公司副总裁，该公司是一家从事人工智能开发和应用的中国公司。2009年11月至2017年8月，他在如皋港口集团有限公司（Rugao Port Group Co.，Ltd.）担任行政总监，该公司是一家专注于港口物流、工业园区建设和木材、煤炭和矿石贸易的中国公司。2004年6月至2009年10月，Cai先生在上海Rishan环保科技有限公司担任经理，该公司是一家经销和零售环保清洁产品的中国公司。Cai先生拥有行政管理学士学位。
- Mingyue Cai has served as independent director and the Chair of the Nominating and Corporate Governance Committee since February 2025. Mr. Cai has been the Vice President at Yitu Safety Technology (Shenzhen) Co., Ltd., a PRC company engages in artificial intelligence development and application. From February 2020 to April 2024, Mr. Cai worked as an independent director and the chair of compensation committee of GD Culture Group Limited (NASDAQ: GDC). From November 2009 to Augt 2017, he was an administrative director at Rugao Port Group Co., Ltd., a PRC company that foces on port logistics, indtrial park construction and timber, coal and ore trade. From June 2004 to October 2009, Mr. Cai worked as a manager at Shanghai Rishan Environmental Protection Technology Co., Ltd., a PRC company that distribute and retail environmentally friendly cleaning products. Mr. Cai graduated from China Central Radio & TV University in 2015 with a major in administration.
- Jing Zhang
-
Jing Zhang，自2025年2月起担任独立董事、审计委员会主任委员。Zhang女士拥有超过25年的财务管理工作经验。2013年7月至今，Zhang女士担任上海Xun Yang Network Technology Co., Ltd.首席财务官。2022年9月至2023年2月，Zhang女士担任Code Chain New Continent Limited Co., Ltd.（纳斯达克股票代码：CCNC）独立董事兼审计委员会主席。2009年3月至2013年7月，Zhang女士担任Zi Guang Intelligence Co., Ltd.上海分公司财务经理。1999年3月至2009年2月，Zhang女士担任八五医院财务部会计、财务总监。Zhang女士于1999年毕业于枣庄学院。
Jing Zhang has served as independent director and the Chair of the Audit Committee since February 2025. Ms. Zhang has more than 25 years of working experience in financial management. Since July 2013, Ms. Zhang has been the Chief Financial Officer of Shanghai Xun Yang Network Technology Co., Ltd. From September 2022 to February 2023, Ms. Zhang served as an independent director and the chair of the audit committee of Code Chain New Continent Limited Co., Ltd. (NASDAQ: CCNC). From March 2009 to July 2013, Ms. Zhang served as the financial manager of Shanghai Branch of Jiangsu Zi Guang Intelligence Co., Ltd. From March 1999 to February 2009, Ms. Zhang served as the accountant and financial director of the Finance Department of the Eight Five Hospital. Ms. Zhang graduated from Zaozhuang University in 1999. - Jing Zhang，自2025年2月起担任独立董事、审计委员会主任委员。Zhang女士拥有超过25年的财务管理工作经验。2013年7月至今，Zhang女士担任上海Xun Yang Network Technology Co., Ltd.首席财务官。2022年9月至2023年2月，Zhang女士担任Code Chain New Continent Limited Co., Ltd.（纳斯达克股票代码：CCNC）独立董事兼审计委员会主席。2009年3月至2013年7月，Zhang女士担任Zi Guang Intelligence Co., Ltd.上海分公司财务经理。1999年3月至2009年2月，Zhang女士担任八五医院财务部会计、财务总监。Zhang女士于1999年毕业于枣庄学院。
- Jing Zhang has served as independent director and the Chair of the Audit Committee since February 2025. Ms. Zhang has more than 25 years of working experience in financial management. Since July 2013, Ms. Zhang has been the Chief Financial Officer of Shanghai Xun Yang Network Technology Co., Ltd. From September 2022 to February 2023, Ms. Zhang served as an independent director and the chair of the audit committee of Code Chain New Continent Limited Co., Ltd. (NASDAQ: CCNC). From March 2009 to July 2013, Ms. Zhang served as the financial manager of Shanghai Branch of Jiangsu Zi Guang Intelligence Co., Ltd. From March 1999 to February 2009, Ms. Zhang served as the accountant and financial director of the Finance Department of the Eight Five Hospital. Ms. Zhang graduated from Zaozhuang University in 1999.
- Steven I Fang Cheng
-
Steven I Fang Cheng，曾担任Advanced Biomed Inc.的董事。自2022年11月起担任首席技术官。2014年加入Advanced Biomed Taiwan。作为联合创始人和首席技术官2013年起任TSRI副研究员（首席研究员）。他的专业研究领域包括生物微流体，生物传感器，癌症诊断和感染检测，微/纳米制造技术，芯片上药物筛选，电动力学/电分析及其生物医学应用，专利设计和植入。2007年获National Cheng Kung University生物医学工程系理学硕士学位，2010年获National Cheng Kung University纳米技术与微系统工程研究所博士学位。
Steven I Fang Cheng has served as Chief Technology Officer since November 2022 and as director since May 2025, respectively. In 2014, Dr. Cheng joined Advanced Biomed Taiwan. as a co founder and CTO. Since 2013, he was an associate research fellow (Principal Investigator) in TSRI. His professional research expertise includes biomicrofluidics, biosensors, cancer diagnosis and infectio detection, micro/nano fabrication technology, on chip drug screening, electrokinetics/electrical analysis and their biomedical applications, patent design and implantation. He received his Master of Science degree from Department of Biomedical Engineering of National Cheng Kung University in Taiwan in 2007 and received his Ph.D. degree from Institute of Nanotechnology & Microsystems Engineering at National Cheng Kung University in 2010. He has great experience in cross disciplinary integration development and novel techniques/products creation on biomedical research. He also has great professional capability and personality characteristic to lead and co operate with top researchers from many different fields. - Steven I Fang Cheng，曾担任Advanced Biomed Inc.的董事。自2022年11月起担任首席技术官。2014年加入Advanced Biomed Taiwan。作为联合创始人和首席技术官2013年起任TSRI副研究员（首席研究员）。他的专业研究领域包括生物微流体，生物传感器，癌症诊断和感染检测，微/纳米制造技术，芯片上药物筛选，电动力学/电分析及其生物医学应用，专利设计和植入。2007年获National Cheng Kung University生物医学工程系理学硕士学位，2010年获National Cheng Kung University纳米技术与微系统工程研究所博士学位。
- Steven I Fang Cheng has served as Chief Technology Officer since November 2022 and as director since May 2025, respectively. In 2014, Dr. Cheng joined Advanced Biomed Taiwan. as a co founder and CTO. Since 2013, he was an associate research fellow (Principal Investigator) in TSRI. His professional research expertise includes biomicrofluidics, biosensors, cancer diagnosis and infectio detection, micro/nano fabrication technology, on chip drug screening, electrokinetics/electrical analysis and their biomedical applications, patent design and implantation. He received his Master of Science degree from Department of Biomedical Engineering of National Cheng Kung University in Taiwan in 2007 and received his Ph.D. degree from Institute of Nanotechnology & Microsystems Engineering at National Cheng Kung University in 2010. He has great experience in cross disciplinary integration development and novel techniques/products creation on biomedical research. He also has great professional capability and personality characteristic to lead and co operate with top researchers from many different fields.
- Cheang I Kei
-
Cheang I Kei，自2025年2月11日起担任独立董事和薪酬委员会主席。她自2022年10月起担任Luso International Banking Ltd.的法律高级经理。她于2019年5月至2022年10月担任中国银行（澳门）法务经理。2016年8月至2019年5月，她担任Luso International Banking Ltd.的法律助理。她于2016年获得澳门理工大学中英文翻译和口译学士学位。
Cheang I Kei has served as independent director and the Chair of the Compensation Committee since February 2025. Ms. Cheang has been the legal senior manager at Lo International Banking Ltd. since October 2022. She served as the legal manager at Bank of China (Macau) from May 2019 to October 2022. She was the legal assistant at Lo International Banking Ltd. beten Augt 2016 and May 2019.Ms. Cheang received her bachelor's degree in Chinese English translation and interpretation from Macau Polytechnic University in 2016. - Cheang I Kei，自2025年2月11日起担任独立董事和薪酬委员会主席。她自2022年10月起担任Luso International Banking Ltd.的法律高级经理。她于2019年5月至2022年10月担任中国银行（澳门）法务经理。2016年8月至2019年5月，她担任Luso International Banking Ltd.的法律助理。她于2016年获得澳门理工大学中英文翻译和口译学士学位。
- Cheang I Kei has served as independent director and the Chair of the Compensation Committee since February 2025. Ms. Cheang has been the legal senior manager at Lo International Banking Ltd. since October 2022. She served as the legal manager at Bank of China (Macau) from May 2019 to October 2022. She was the legal assistant at Lo International Banking Ltd. beten Augt 2016 and May 2019.Ms. Cheang received her bachelor's degree in Chinese English translation and interpretation from Macau Polytechnic University in 2016.
高管简历
中英对照 | 中文 | 英文- Yi Lu
Yi Lu，自2022年11月起担任Advanced Biomed Inc.首席科学官兼董事长。他自2014年6月起担任Advanced Biomed Taiwan的董事长兼首席科学官。从2020年1月到2022年10月，他担任HFC Semiconductor的董事长。Lu博士此前曾担任Nextchip Semiconductor Corporation（一家专门从事集成电路生产的半导体代工厂）的董事长（2016年2月至2019年12月）。他带领公司投资200亿元，建成安徽省首条12英寸集成电路生产线。从2004年1月到2007年12月，他是Cypress Semiconductor的高级执行官。从2001年5月到2004年1月，他是Cascade Semiconductor（被Cypress Semiconductor Corporation （Nasdaq： CY）收购）的创始人、董事长兼首席执行官。
Yi Lu has served as Chairman of the Board since November 2022 and as Chief Executive Officer since March 2024. He has been the Chairman and Chief Science Officer of Advanced Biomed Taiwan since June 2014. He was the Chairman of HFC Semiconductor from January 2020 to October 2022 and was responsible for the company's strategic development. Dr. Lu previoly served as Chairman of Nextchip Semiconductor Corporation, a semiconductor foundry specializing in integrated circuit production, from February 2016 to December 2019 and led the company to launch the first 12 inch integrated circuit production line in Anhui Province with an investment of RMB20 billion. From January 2004 to December 2007, he was the senior executive of Cypress Semiconductor, overseeing the company's biness operation. From May 2001 to January 2004, he was the founder, Chairman and CEO of Cascade Semiconductor, which was acquired by Cypress Semiconductor Corporation (Nasdaq: CY), and managed the overall operations of the company. Dr. Lu received a Doctor of Philosophy from the University of Florida in 1994.- Yi Lu，自2022年11月起担任Advanced Biomed Inc.首席科学官兼董事长。他自2014年6月起担任Advanced Biomed Taiwan的董事长兼首席科学官。从2020年1月到2022年10月，他担任HFC Semiconductor的董事长。Lu博士此前曾担任Nextchip Semiconductor Corporation（一家专门从事集成电路生产的半导体代工厂）的董事长（2016年2月至2019年12月）。他带领公司投资200亿元，建成安徽省首条12英寸集成电路生产线。从2004年1月到2007年12月，他是Cypress Semiconductor的高级执行官。从2001年5月到2004年1月，他是Cascade Semiconductor（被Cypress Semiconductor Corporation （Nasdaq： CY）收购）的创始人、董事长兼首席执行官。
- Yi Lu has served as Chairman of the Board since November 2022 and as Chief Executive Officer since March 2024. He has been the Chairman and Chief Science Officer of Advanced Biomed Taiwan since June 2014. He was the Chairman of HFC Semiconductor from January 2020 to October 2022 and was responsible for the company's strategic development. Dr. Lu previoly served as Chairman of Nextchip Semiconductor Corporation, a semiconductor foundry specializing in integrated circuit production, from February 2016 to December 2019 and led the company to launch the first 12 inch integrated circuit production line in Anhui Province with an investment of RMB20 billion. From January 2004 to December 2007, he was the senior executive of Cypress Semiconductor, overseeing the company's biness operation. From May 2001 to January 2004, he was the founder, Chairman and CEO of Cascade Semiconductor, which was acquired by Cypress Semiconductor Corporation (Nasdaq: CY), and managed the overall operations of the company. Dr. Lu received a Doctor of Philosophy from the University of Florida in 1994.
- Mingze Yin
Mingze Yin，曾担任Advanced Biomed Inc.；自2022年11月起担任首席财务官。他一直担任Shanghai Sglcell Biotech Co.， Ltd.的首席财务官（2021年1月以来）。2017年3月至2021年12月，Yin先生担任Shanghai Guangdian Asset Management Co., Ltd.董事。2020年2月至2020年11月，他担任TMSR控股有限公司（纳斯达克股票代码：TMSR）的独立董事。2018年2月至2018年11月，Yin先生担任Planet Green Holdings Corp.（纽约证券交易所代码：PLAG）的投资者关系经理。2015年11月至2017年2月，Yin先生担任Zhongshan Securities Co., Ltd.投资银行部高级经理。2012年10月至2015年10月，他担任BDO China Shu Lun Pan会计师事务所高级审计经理。他于2011年获得江苏海洋大学管理学学士学位。
Mingze Yin has served as Chief Financial Officer since November 2022. He has over 11 years of experience in the financial and investment banking indtry. He has been the Chief Financial Officer of Shanghai Sglcell Biotech Co., Ltd. since January 2021 and oversees its finance department. From March 2017 to December 2021, Mr. Yin was Director of Shanghai Guangdian Asset Management Co., Ltd., where he participated in all major corporate decisions and financial compliance matters. From February 2020 to November 2020, he was an independent director of TMSR Holding Company Limited (Nasdaq: TMSR) and a member of its Audit Committee, Nominating and Governance Committee, and Compensation Committee. From February 2018 to November 2018, Mr. Yin was the investors relations manager of Planet Green Holdings Corp. (NYSE: PLAG). From November 2015 to February 2017, Mr. Yin was a senior manager of the Investment Banking Department of Zhongshan Securities Co., Ltd. From October 2012 to October 2015, he was the senior audit manager of BDO China Shu Lun Pan Certified Public Accountants LLP. Mr. Yin is a certified internal auditor and obtained his Bachelor of Management from Jiangsu Haiyang University in 2011.- Mingze Yin，曾担任Advanced Biomed Inc.；自2022年11月起担任首席财务官。他一直担任Shanghai Sglcell Biotech Co.， Ltd.的首席财务官（2021年1月以来）。2017年3月至2021年12月，Yin先生担任Shanghai Guangdian Asset Management Co., Ltd.董事。2020年2月至2020年11月，他担任TMSR控股有限公司（纳斯达克股票代码：TMSR）的独立董事。2018年2月至2018年11月，Yin先生担任Planet Green Holdings Corp.（纽约证券交易所代码：PLAG）的投资者关系经理。2015年11月至2017年2月，Yin先生担任Zhongshan Securities Co., Ltd.投资银行部高级经理。2012年10月至2015年10月，他担任BDO China Shu Lun Pan会计师事务所高级审计经理。他于2011年获得江苏海洋大学管理学学士学位。
- Mingze Yin has served as Chief Financial Officer since November 2022. He has over 11 years of experience in the financial and investment banking indtry. He has been the Chief Financial Officer of Shanghai Sglcell Biotech Co., Ltd. since January 2021 and oversees its finance department. From March 2017 to December 2021, Mr. Yin was Director of Shanghai Guangdian Asset Management Co., Ltd., where he participated in all major corporate decisions and financial compliance matters. From February 2020 to November 2020, he was an independent director of TMSR Holding Company Limited (Nasdaq: TMSR) and a member of its Audit Committee, Nominating and Governance Committee, and Compensation Committee. From February 2018 to November 2018, Mr. Yin was the investors relations manager of Planet Green Holdings Corp. (NYSE: PLAG). From November 2015 to February 2017, Mr. Yin was a senior manager of the Investment Banking Department of Zhongshan Securities Co., Ltd. From October 2012 to October 2015, he was the senior audit manager of BDO China Shu Lun Pan Certified Public Accountants LLP. Mr. Yin is a certified internal auditor and obtained his Bachelor of Management from Jiangsu Haiyang University in 2011.
- Steven I Fang Cheng
Steven I Fang Cheng，曾担任Advanced Biomed Inc.的董事。自2022年11月起担任首席技术官。2014年加入Advanced Biomed Taiwan。作为联合创始人和首席技术官2013年起任TSRI副研究员（首席研究员）。他的专业研究领域包括生物微流体，生物传感器，癌症诊断和感染检测，微/纳米制造技术，芯片上药物筛选，电动力学/电分析及其生物医学应用，专利设计和植入。2007年获National Cheng Kung University生物医学工程系理学硕士学位，2010年获National Cheng Kung University纳米技术与微系统工程研究所博士学位。
Steven I Fang Cheng has served as Chief Technology Officer since November 2022 and as director since May 2025, respectively. In 2014, Dr. Cheng joined Advanced Biomed Taiwan. as a co founder and CTO. Since 2013, he was an associate research fellow (Principal Investigator) in TSRI. His professional research expertise includes biomicrofluidics, biosensors, cancer diagnosis and infectio detection, micro/nano fabrication technology, on chip drug screening, electrokinetics/electrical analysis and their biomedical applications, patent design and implantation. He received his Master of Science degree from Department of Biomedical Engineering of National Cheng Kung University in Taiwan in 2007 and received his Ph.D. degree from Institute of Nanotechnology & Microsystems Engineering at National Cheng Kung University in 2010. He has great experience in cross disciplinary integration development and novel techniques/products creation on biomedical research. He also has great professional capability and personality characteristic to lead and co operate with top researchers from many different fields.- Steven I Fang Cheng，曾担任Advanced Biomed Inc.的董事。自2022年11月起担任首席技术官。2014年加入Advanced Biomed Taiwan。作为联合创始人和首席技术官2013年起任TSRI副研究员（首席研究员）。他的专业研究领域包括生物微流体，生物传感器，癌症诊断和感染检测，微/纳米制造技术，芯片上药物筛选，电动力学/电分析及其生物医学应用，专利设计和植入。2007年获National Cheng Kung University生物医学工程系理学硕士学位，2010年获National Cheng Kung University纳米技术与微系统工程研究所博士学位。
- Steven I Fang Cheng has served as Chief Technology Officer since November 2022 and as director since May 2025, respectively. In 2014, Dr. Cheng joined Advanced Biomed Taiwan. as a co founder and CTO. Since 2013, he was an associate research fellow (Principal Investigator) in TSRI. His professional research expertise includes biomicrofluidics, biosensors, cancer diagnosis and infectio detection, micro/nano fabrication technology, on chip drug screening, electrokinetics/electrical analysis and their biomedical applications, patent design and implantation. He received his Master of Science degree from Department of Biomedical Engineering of National Cheng Kung University in Taiwan in 2007 and received his Ph.D. degree from Institute of Nanotechnology & Microsystems Engineering at National Cheng Kung University in 2010. He has great experience in cross disciplinary integration development and novel techniques/products creation on biomedical research. He also has great professional capability and personality characteristic to lead and co operate with top researchers from many different fields.